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intake would be 8.9 g leucine (6.1 1 2.8 g from supplement) and
11.7 g leucine on a training day (6.1 1 2 supplements) (Figure 1).
This would correspond to leucine intakes in a protein diet contain-
ing 1.2 g or 1.6 g protein/kg body weight per day, respectively
(Figure 1). To compare, the calculated leucine intake in the inter-
vention group was below the median daily leucine intake of 10.3 g
leucine/d (in a 95-kg subject) as reported in the United Kingdom
(5), and for older adults the current recommended level of protein
intake is 1.0–1.2 g/kg per day, or 1.2–1.5 g/kg per day when com-
bined with a chronic condition (6). Together, this substantiates that
the additional leucine intake due to the supplement is not supra-
physiologic but within the range of reported intakes in dietary sur-
veys and the current international recommendations.
Acute studies have been conducted to define a maximum tolerable
level of leucine consumption per day. In a recent study, Pencharz et al.
(7) based their advice on the upper level of leucine intake on the
maximum amount of leucine that could still be oxidized. They estimated
on the basis of these acute studies that a dose ,550 mg leucine/kg
body weight per day would pose no risk to health. This corresponds
to a daily consumption of 52.3 g leucine when calculating with a 95-kg
subject, which is much higher than the estimated leucine consumption
over the day in our intervention study. A supplementation study
during 6 mo with 3 times 2.5 g leucine/d in addition to the normal diet
(;0.95 g protein/kg body weight per day) was conducted in older
patients with type 2 diabetes (8). Leucine supplementation resulted in
a modest increase of;10% in fasted plasma leucine concentrations after
2–4 wk without a progressive increase at later time points. In this con-
trolled study, no adverse effects of leucine were reported. Intakes
of protein and leucine in our study were within the normal range
(Figure 1); consequently, we did not anticipate elevated concentra-
tions of insulin-like growth factor I (IGF-I) and mammalian target of
rapamycin (mTOR) activation beyond normal physiologic levels. We
agree, however, with Bernstein et al. that longer-term studies on relevant
clinical outcome variables related to the risk of chronic disease should
be considered as further proof of safety.
High-protein diets (25% of energy intake) support weight
maintenance (9). In the present study, we show that the special-
ized supplement provides the benefit of preserving muscle mass
during weight loss in older obese individuals. Whether consum-
ing the supplement would also support weight maintenance was
not studied, but muscle preservation may also have long-lasting
benefits during weight maintenance.
In summary, the amount of protein and particularly leucine in the
present study can be considered at the high end of the normal
distribution of intake. The safest way to proceed is to grow older
without becoming obese.
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Regular physical activity: a little is good, but is it
good enough?
Dear Editor:
Ekelund et al. (1) nicely showed that physical inactivity causes an
approximate twofold increase in the numbers of deaths compared
FIGURE 1 Leucine intake in grams per day for different amounts of
protein and supplement intake compared with international standards for
protein and leucine intakes. Leucine intake per day was calculated on the
basis of a 95-kg subject. The supplement, control diet, control diet plus 1
supplement, and control diet plus 2 supplements (training day) are shown
in the context of the EAR and RDA for leucine, the median leucine
intake in the United Kingdom (5), and the safe level of leucine intake
(7) as well as different levels of protein intake considered to be safe (3,
6). EAR, Estimated Average Requirement; RDA, Recommended Dietary
Allowance.



























with those attributable to obesity [BMI (in kg/m2) .30] in a Euro-
pean cohort (n ¼ 334,161) that was followed up to 12.4 y
on average. Physical activity (PA) levels were estimated by using
a standardized questionnaire or in-person interviews and were found
to be inversely associated with all-cause mortality at all levels of
BMI and waist circumference. Another important finding from their
study is that substantial survival benefits may be achieved by fairly
small amounts of moderate-intensity PA: that is, ;20 min/d of brisk
walking, which is below the current PA recommendations of 30
min/d on most, if not all, days of the week (or 150 min/wk). These
important findings in Caucasians are in line with those recently
reported in an Asiatic cohort, in whom 15 min/d or 90 min/wk of
moderate-intensity PAwas associated with lower all-cause mor-
tality, even for persons at risk of cardiovascular disease (2).
The medical relevance of the study by Ekelund et al. (1) should be
acknowledged. It was certainly well powered to show the mortality
benefits of small PA doses and thus to provide further epidemiologic
support for PA promotion worldwide. And yet we are concerned about
the possibility that the finding that even small PA amounts are clini-
cally relevant might be misinterpreted by the general public as well as
by some health professionals. Indeed, recognizing the benefits of
small PA doses is important but at the same time might somehow
dilute what we think is also a main message arising from the bulk of
research in the field: that is, that the main epidemiologic benefits of
exercise can be even stronger at high PA doses, with recent research
also showing greater gains in life expectancy (14.5 y; 95% CI: 4.3,
4.7 y) with PA levels equivalent to 450 min/wk of brisk walking (3).
On the other hand, there is growing evidence that the largest
epidemiologic benefits of PA against a major cause of death world-
wide, cancer, are dose-related, at least for some main cancer types,
particularly colon cancer. In fact, the last World Cancer Research
Fund report on PA and cancer prevention establishes the evidence of
a dose-response effect for colorectal cancer, and especially for colon
cancer (4). Engaging in 150 min/wk of recreational PA (e.g.,
walking) is associated with lower all-cause mortality after colorectal
cancer diagnosis (5). Yet, 7 h/wk (60 min/d) of moderate-to-
vigorous PA has been reported to be associated with lower risk of
total cancer mortality (HR: 0.89; 95% CI: 0.84, 0.94; P , 0.001),
with the link being especially strong for colon (HR: 0.70; 95% CI:
0.57, 0.85; P , 0.001), liver (HR: 0.71; 95% CI: 0.52, 0.98; P ¼
0.012), and lung (HR: 0.84; 95% CI: 0.77, 0.92; P , 0.001) cancers
(6). Furthermore, a recent meta-analysis from our group showed
a considerably lower cancer-related mortality in those humans en-
gaging in the highest PA levels—that are, elite athletes of various
sport disciplines (n ¼ 12,119, mostly men), including Tour de
France finishers—than in the general population (standard mortality
ratio: 0.60; 95% CI: 0.38, 0.94; P ¼ 0.03) (7).
Another concern is ensuring that the PA levels of cancer survi-
vors are high enough, because current PA recommendations of
150 min/wk of moderate PA might actually be insufficient for
this population, as we recently reviewed (8). In the cohorts of
US cancer survivors in whom PA was measured objectively by
using accelerometry, average levels of moderate PA (brisk walk-
ing) were even below 20 min/d (see reference 7 for a review). In
contrast, we recently reported, also with the use of accelerometry,
that the vast majority of a cohort of Spanish middle-aged cancer
survivors of both genders performed, on average, 356 min/wk
(;50 min/d) of moderate-to-vigorous PA (9). Despite such appar-
ently good news, these high PA levels were not accompanied by
a “healthy” cardiometabolic profile. Notably, 33% of the subjects
were obese and the mean levels of cardiorespiratory fitness (CRF;
determined as peak oxygen uptake) of this cohort was 7.7 meta-
bolic equivalents (METs), with ;50% of subjects not reaching
a CRF of 8 METs. Any CRF value ,8 METs is indicative of an
increased risk of mortality and cardiovascular events in middle-
aged men and women aged 40–60 y, on average (10), and cardio-
vascular disease is the leading cause of morbidity and mortality
among long-term cancer survivors. In fact, men with a CRF
,8 METs have a more than threefold higher risk of dying of di-
gestive disease (bowel, colorectal, liver cancer) than do those with
a CRF 11 METs (11).
In summary, although ;20 min/d of PA is certainly much better
than inactivity, as elegantly shown by Ekelund et al. (1), we question
whether this fairly small dose might be enough to bring a substantial
clinical benefit in certain cases, especially for cancer prevention and
among cancer survivors. Further epidemiologic research is also
needed using objective and reliable assessment of PA, ideally with
accelerometry, to determine the optimal PA dose associated with the
highest epidemiologic benefits in different population groups.
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Reply to H Pareja-Galeano et al.
Dear Editor:
We appreciate the interest from Pareja-Galeano et al. in our study and
acknowledge that they considered our study well powered and clinically
relevant. Similar to others (1), our results suggested that the greatest
reduction in the hazard of mortality was found between the “inactive”
and the “moderately inactive” group. This reduction was observed across
general and abdominal obesity groups, suggesting health benefits from
increasing physical activity (PA) regardless of adiposity. On the basis of
our validation study (2), we estimated that the difference between the
“inactive” and “moderately inactive” group was equivalent to ;20 min
of brisk walking each day. This equates to 140 min/wk, which is almost
in line with current PA recommendations for public health (3–5).
Wedonot dispute the health benefits associatedwith higher levels of PA,
which Pareja-Galeano et al. have highlighted, but the keymessage fromour
studywas that therewould be substantial public health benefits frompeople
in the inactive group engaging in even a small amount of PA each day.
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Biomarkers of dairy fat
Dear Editor:
There were 2 interesting articles in a recent issue of the Journal in
which odd-chain fatty acids (15:0 and 17:0) were used as circulating
biomarkers of dairy fat (1, 2). In one of the studies (1), serum penta-
decanoic acid (15:0) was shown to be inversely associated with in-
cident type 2 diabetes, and in the other study (2) the association of
pentadecanoic acid and heptadecanoic acid (17:0) with the risk of
incident stroke was studied and no significant association was found.
These odd-chain fatty acids are considered to be validated biomarkers
for dairy fat and they correlated with dairy consumption in many
studies (1–4). However, the association between the intake of dairy
fat and the relative serum content of heptadecanoic acid has not been
clear in all studies (5, 6). In a large cohort study [EPIC (European
Prospective Investigation into Cancer and Nutrition)], there was
a strong positive ecologic correlation (r ¼ 0.8, P  0.01) between
the total intake of fish and plasma concentration of heptadecanoic
acid, whereas there was no correlation between heptadecanoic acid
or pentadecanoic acid and dairy products (6). Accordingly, we have
seen in our studies (MA Lankinen et al., 2015) a positive correlation
between pentadecanoic and heptadecanoinc acids with DHA in
plasma phospholipids. The fatty acid heptadecanoic acid is present
in the fat of fish (0.31–2.0% depending on fish species) (7, 8). Salmon
contains ;40 mg heptadecanoic acid and 20 mg pentadecanoic acid
per 100 g (9). Therefore, we are a bit concerned if these odd-chain
fatty acids are considered to be a valid biomarker for dairy fat intake
in populations who consume considerable amounts of fish. In pop-
ulations with a high consumption of dairy fat and a low consumption
of fish, odd-chain fatty acids are probably valid biomarkers for dairy
fat intake. In populations who consume fish, the presence of odd-
chain fatty acids in fish should be taken into account to avoid
misleading conclusions.
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